Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $6.7 million.

  • SAB Biotherapeutics' Gains from Investment Securities rose 117.98% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 117.98%. This contributed to the annual value of $3.0 million for FY2024, which is 194.00% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Gains from Investment Securities is $6.7 million, which was up 129.95% from $2.9 million recorded in Q2 2025.
  • SAB Biotherapeutics' Gains from Investment Securities' 5-year high stood at $9.9 million during Q2 2023, with a 5-year trough of -$7.8 million in Q1 2022.
  • Over the past 3 years, SAB Biotherapeutics' median Gains from Investment Securities value was $3.0 million (recorded in 2025), while the average stood at $3.5 million.
  • Data for SAB Biotherapeutics' Gains from Investment Securities shows a peak YoY increase of 415,216.78% (in 2022) and a maximum YoY decrease of 17,362.81% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Gains from Investment Securities stood at $3.9 million in 2021, then plummeted by 100.94% to -$36,586 in 2022, then soared by 13,020.42% to $4.7 million in 2023, then tumbled by 51.21% to $2.3 million in 2024, then soared by 117.98% to $6.7 million in 2025.
  • Its Gains from Investment Securities was $6.7 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.0 million in Q1 2025.